Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
In a rare move for the UK’s MHRA (Medicines and Healthcare products Regulatory Agency), the regulator has helped to “future-proof” CMO Fujifilm Diosynth Biotechnologies’ mammalian cell culture manufacturing facility in Billingham, UK against potential...
WuXi PharmaTech subsidiary WuXi Biologics has begun construction on a new $150m biologics manufacturing facility in Wuxi, China, which is expected to be the largest mammalian cell culture manufacturing sire using disposable bioreactors in the world.
Cheaper disposable manufacturing techs and increased demand for outsourced production will see more CMOs enter the contracting sector according to HighTech Business Decisions
Rentschler Biotechnologie has increased single-use bioreactor capacity at its manufacturing site in Laupheim, Germany and is moving forward with plans to invest €25m ($27m) in a new stainless steel system in the next few months.
Chinese cancer drug developer BeiGene will create production cell lines using a platform developed by Sigma Aldrich's custom manufacturing services business.
Novasep has signed a €4.7m ($5.4m) agreement with Celladon, a clinical-stage biotechnology company, to prepare to supply the drug substance for the heart failure treatment Mydicar.
Peregrine Pharmaceuticals is expanding its contract manufacturing capacity to meet growing client demand and to produce its own monoclonal antibody bavituximab, the company has revealed.
Analytical and bioanalytical service provider SGS has made significant changes to its global network over the past few months to stay ahead of the competition curve.
The products, unveiled at BioProcess International in Boston this week, will help industry with their upstream and downstream processing and include an anti-CHO host cell protein detection kit, the first single-use fermentor, and a new mammalian expression...
Baxter International plans to set up a new global R&D center in Cambridge, Mass, for Baxalta, its biopharmaceuticals spinoff, which is expected be formally incorporated next year and headquartered in northern Illinois.
Patheon has acquired Gallus BioPharmaceuticals adding two US biologics plants and says with an industry shift towards medium sized bioreactors it now holds the market advantage.
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
Knowing about manufacturing innovations as soon as possible is more important for BioPharmas than for their small molecule counterparts according to an MIT Professor interviewed by our new sister site BioPharma-Reporter.com
GE Healthcare and iBio are in talks about future projects after confirming they are working on a plant-based vaccine manufacturing site for Brazilian drugmaker Fiocruz/Bio-Manguinhosin.
As the dissolution of Angel continues, its core manufacturing facility has been bought by AB Technology ensuring long term operations and rescuing 23 jobs.
Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Prokarium – a biotech company that was formerly part of UK CMO Cobra Biologics spin-out - has bought an oral vaccine technology from Emergent BioSolutions.
Lonza is targeting the gene therapy sector through a new partnership with Avalanche Biotechnologies that will seek to outlicense viral vector tech and process development knowhow.
March has already been a busy month for the biomanufacturing technology sector and here is in-Pharmatechnologist.com’s round-up of some of the developments so far.
Sartorius Stedim Biotech (SSB) says its partnership with Refine Technology will help meet demand for greater connectivity between retention devices and bioreactors and save Pharmas time and money